Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Featured Story
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Written by Jeffrey Neal Johnson. Article Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently hit its 52-week low, closing just above $100 in the last trading days of March. The sharp downturn has left many asking whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’ situation suggests a potential disconnect between market sentiment and operational reality. The key question: Is the market’s pessimism justified, or has a meaningful value opportunity opened for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn’t fall without reason. Its recent decline stems from two distinct pressures. The first is internal: Abbott Laboratories’ Nutrition segment. Fourth-quarter 2025 results showed a 9.1% organic sales decline in Nutrition, mainly due to U.S. pediatric market-share losses and pricing dynamics that constrained volume. Management has been transparent about the issue and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and at least eight new product launches in 2026 aimed at reigniting volume growth, with a return to growth expected in the second half of the year. The second pressure is external and broader: a rotation of capital away from defensive sectors. In periods of economic optimism, investors often move money out of stable healthcare names and into higher-beta areas like artificial intelligence and the energy sector seeking faster returns. That trend has weighed on many fundamentally sound healthcare companies, including Abbott, for reasons unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works toward a short-term recovery, Abbott Laboratories' core businesses remain robust—led by its largest and most profitable division, Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s health is most evident in these high-performing areas.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. The product, which lets users track glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and remains a primary growth driver. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular care. Its Electrophysiology business grew at a double-digit clip, while Structural Heart posted strong organic growth of 8.7%. That strength comes from a portfolio of best-in-class products—such as MitraClip and TriClip for minimally invasive valve repair—and a pipeline of innovations, including the recently FDA-approved Volt PFA System for atrial fibrillation. Abbott is also positioning for future growth through the acquisition of Exact Sciences, a leader in non-invasive cancer screening (best known for Cologuard). The deal would immediately expand Abbott’s footprint into the fast-growing, multi-billion-dollar cancer diagnostics market, adding a new high-growth vertical poised to contribute materially to revenue over time. That positive outlook is not just company rhetoric; it is reflected by analysts. Wall Street currently assigns a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and suggesting many analysts see the stock as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term, income-focused investors, Abbott’s dividend is a compelling reason to consider the stock. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital through all market cycles. The recent drop in Abbott’s stock price has a clear benefit for new investors: a higher yield. At current prices, Abbott yields about 2.5%, letting investors lock in a higher income rate from a historically reliable payer. The payout is also well-supported: the dividend represents roughly 68% of earnings and only about 37% of operating cash flow, indicating ample cash generation to cover payments and room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott Laboratories appears disconnected from its business fundamentals. While temporary headwinds in Nutrition and sector-wide rotation have depressed the stock price, Abbott’s core growth engines—especially Medical Devices and Diabetes Care—are accelerating. The dividend remains a bedrock of reliability, and strategic catalysts like the Exact Sciences acquisition could add meaningful long-term growth. For long-term investors, the current valuation creates a notable gap between market price and intrinsic value that merits serious consideration. |
